MDGL
Madrigal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$541.08
−0.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 958.4M | 180.1M | — | — |
| Cost of Revenue | 109.4M | 56.1M | 6.2M | — | — |
| Gross Profit | 1.2B | 902.3M | 173.9M | — | — |
| Operating Expenses | |||||
| R&D Expense | 490.1M | 388.5M | 236.7M | 272.4M | 245.4M |
| SG&A Expense | 1.0B | 813.8M | 435.1M | 108.1M | 48.1M |
| General & Admin Expense | 209.1M | — | — | 108.1M | 48.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.5B | 1.2B | 671.8M | 380.5M | 293.6M |
| Cost and Expenses | 1.6B | 1.3B | 678.0M | 380.5M | 293.6M |
| Operating Income (EBIT) | (322.6M) | (300.1M) | (497.9M) | (380.5M) | (293.6M) |
| Non-Operating | |||||
| Interest Income | 35.1M | 37.4M | 46.7M | 19.6M | 2.2M |
| Interest Expense | 15.6M | 22.3M | 14.7M | 12.7M | 4.0M |
| Net Interest Income | 19.5M | 15.1M | 32.0M | 6.9M | (1.8M) |
| Other Non-Op Income/Expense | (2.5M) | 11.8M | 32.0M | 6.9M | (1.8M) |
| Non-Operating Income (excl Interest) | (22.7M) | (34.1M) | (46.7M) | (19.6M) | (2.2M) |
| EBT (Pre-Tax Income) | (325.1M) | (288.3M) | (465.9M) | (373.6M) | (295.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (325.1M) | (288.3M) | (465.9M) | (373.6M) | (295.4M) |
| Earnings from Cont. Ops | (325.1M) | (288.3M) | (465.9M) | (373.6M) | (295.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (325.1M) | (288.3M) | (465.9M) | (373.6M) | (295.4M) |
| Per Share | |||||
| Basic EPS | ($12.89) | ($12.85) | ($21.90) | ($19.99) | ($17.23) |
| Diluted EPS | ($12.89) | ($12.85) | ($21.90) | ($19.99) | ($17.23) |
| Revenue Per Share | $44.05 | $42.72 | $8.47 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 29.1M | 22.4M | 21.3M | 18.7M | 17.1M |
| Diluted Shares Outstanding | 29.1M | 22.4M | 21.3M | 18.7M | 17.1M |
| Profitability Metrics | |||||
| EBITDA | (298.8M) | (264.5M) | (450.1M) | (360.4M) | (290.9M) |
| D&A | 1.1M | 1.5M | 1.1M | 527.0K | 467.0K |
| EBIT | (299.9M) | (266.0M) | (451.2M) | (360.9M) | (291.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026